- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04699422
Serratus Anterior Plane Block Versus Standard of Care After Totally Endoscopic Aortic Valve Replacement
Serratus Anterior Plane Block Versus Standard of Care After Totally Endoscopic Aortic Valve Replacement: a Double-blinded Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During the last two decades, cardiac surgical techniques changed dramatically. Evidence for good short and long-term outcome after endovascular and minimally invasive procedures is rising. The goal of avoiding sternotomy is earlier patient recovery without compromising safety. Therefore, enhanced recovery after surgery (ERAS) protocols have been implemented to aim for early extubation and ambulation. Analgesic regimens after cardiac surgery did not change significant however. Opioids remain the cornerstone of analgesia in the postoperative cardiac surgical care units, despite known side effects as nausea, constipation and risk for addiction. Neuraxial anesthetic techniques after cardiac surgery have been studied and validated to reduce opioid consumption. Their implementation in clinical practice however remains limited for two reasons. First, heparinization is required for cardiac surgery, which increases the risk neuraxial hematoma after neuraxial anesthesia, leading to deleterious complications as paraplegia. Secondly, neuraxial anesthesia induces orthosympathicolysis, enhancing vasoplegia after cardiac surgery. However, fascial plane blocks in cardiac surgery since peripheral blocks do not induce sympathicolysis and consequences of chest wall hematoma are limited.
In 2013, Blanco described the serratus anterior plane (SAP) block as an analgesic option for chest wall surgery. In this fascial plane block, local anesthetics are injected in the plane beneath the anterior serratus muscle and in the plane between latissimus dorsi and serratus anterior in an ultrasound guided manner. SAP block provides analgesia in dermatomes T2-T9. Recently, successful analgesia after SAP block has been demonstrated for soft tissue chest wall surgery, thoracotomy and rib fractures. No major side effects were reported. More specifically, no sympatholytic effects or chest wall hematoma were observed. However, up to now no prospective studies assessing the analgesic efficacy of SAP block after cardiac surgery are published. Two retrospective studies show conflicting results. Berthoud et al. retrospectively compared SAP block to continuous wound infusion after different types of minimally invasive cardiac surgery (MICS) and found reduced morphine consumption as well as shorter intensive care and hospital length of stay after SAP block. In contrast, Moll et al. found no difference in opioid consumption between SAP block and no block in patients after robotic coronary artery bypass grafting (rCABG). The authors comment they only performed the deep component of the SAP block, and some surgical entry points were outside dermatomes T2-T7.
Totally endoscopic aortic valve replacement (AVR) is a novel minimally invasive cardiosurgical technique. Surgical incision is made anteriorly in intercostal space two on the right hemithorax. Since intercostal space two is innervated by dermatomes T2-T3, somatic analgesia can be obtained with SAP block. In addition with a favorable safety profile and a minimal/non-existent risk of evoking sympatholytic effects, a SAP block may be a suitable analgesic technique to prevent/minimize postoperative pain after totally endoscopic AVR surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hasselt, Belgium, 3500
- Dr Bjorn Stessel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled for elective aortic valve replacement surgery via right anterolateral thoracotomy
- Adult patients (minimally 18 years old)
- EuroScore ii < 3%
- Bodyweight > 50 kg
Exclusion Criteria:
- Refusal to participate
- Inability to communicate due to language or neurologic barriers
- Inability to control and self-administer opioids with PCIA or to comprehend the NRS pain score due to confusion or learning difficulties
- Chronic use of opioids
- Chronic use of analgesic antidepressants and/or antiepileptics
- History of major trauma or surgery to right chest wall
- History of chronic pain at right chest wall
- Allergy to opioids and/or local anesthetics
- Allergy to acetaminophen
- Morbid obesity (BMI > 35)
- Pregnancy
- Peroperative events compromising early postoperative recovery (aortic dissection, systolic anterior motion of the mitral valve, cardiac tamponade, ..)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Experimental group
Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.
|
The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment).
Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment.
After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues.
The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles.
10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
Other Names:
|
Sham Comparator: Control group
Patients in the control group will receive postoperative PCIA with Piritramide.
|
A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative opioid consumption by patient-controlled intravenous analgesia (PCIA)
Time Frame: 24 hours after performing the SAP block
|
Piritramide consumption (mg) will be directly read from the PCIA-system after 24 hours.
|
24 hours after performing the SAP block
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid consumption during predetermined time intervals after surgery
Time Frame: Every 4 hours until 24 hours after placement of the SAP block
|
Piritramide consumption (mg) will be directly read from the PCIA-system at predetermined time intervals after performing the SAP block.
|
Every 4 hours until 24 hours after placement of the SAP block
|
Opioid free patients first 24 postoperative hours
Time Frame: First 24 hours
|
Number of patients that do not require any opioids within the first 24 hours after surgery.
|
First 24 hours
|
Opioid free patients during hospital length of stay
Time Frame: Through study completion, an average of 7 days
|
Number of patients that do not require any opioids during the hospital length of stay
|
Through study completion, an average of 7 days
|
Postoperative pain score in rest
Time Frame: 4, 8, 12, and 24 hours after performing the SAP block and at postoperative day 7.
|
The postoperative pain on the surgical site is evaluated based on an 11-points numeric scale (Numerical Rating Sale - NRS) where 0 = no pain and 10 = worst pain ever.
|
4, 8, 12, and 24 hours after performing the SAP block and at postoperative day 7.
|
Quality of recovery after totally endoscopic aortic valve replacement
Time Frame: Postoperative days 2 and 7
|
Quality of recovery will be assessed via the 5-Dimensional European Quality of Life (EQ5D) and 36-Item Short Form Health Survey (SF-36) questionnaires concerning mobility, self care, daily activities and pain.
|
Postoperative days 2 and 7
|
Overall patient satisfaction with analgesic therapy
Time Frame: 24 hours after performing the serratus anterior plane block at postoperative day 1
|
Overall patient satisfaction with analgesic therapy will be assessed with an 11-point Numeric Rating Scale (where 0 = not satisfied at all and 10 = extremely satisfied).
|
24 hours after performing the serratus anterior plane block at postoperative day 1
|
Postoperative nausea and vomiting (PONV)
Time Frame: 24 hours after performing the serratus anterior plane block at postoperative day 1
|
The simplified postoperative nausea and vomiting (PONV) impact scale will be used to assess PONV.
The scale ranges from 0 to 6, where 0 means no nausea/vomiting.
Clinically important PONV will be defined as a score of 5 or more.
|
24 hours after performing the serratus anterior plane block at postoperative day 1
|
Constipation
Time Frame: Until postoperative day 7
|
Time to first defecation (postoperative days) or need for laxatives during hospital stay.
|
Until postoperative day 7
|
Time to extubation
Time Frame: Throughout study completion, an average of 7 days
|
Time from arrival to the ICU until extubation in minutes.
|
Throughout study completion, an average of 7 days
|
ICU length of stay
Time Frame: Until postoperative day 7
|
Time from arrival to the ICU until meeting discharge criteria to the ward in postoperative hours.
|
Until postoperative day 7
|
Hospital length of stay
Time Frame: Through study completion, an average of 7 days
|
Time to discharge out of the hospital in postoperative days (day of surgery = day 0)
|
Through study completion, an average of 7 days
|
Pneumonia
Time Frame: Until postoperative day 7
|
Defined as empirical antibiotic therapy for suspicion of pneumonia during hospital stay, in number of patients.
|
Until postoperative day 7
|
Duration of vasopressor infusion
Time Frame: Until postoperative day 7
|
Time from arrival to the ICU until full weaning from vasoactive substances (eg norepinephrine) in minutes.
Patients not requiring any vasopressors will be excluded from this secondary outcome parameter.
|
Until postoperative day 7
|
Subcutaneous emphysema
Time Frame: 24 hours after performing the serratus anterior plane block at postoperative day 7
|
Number of patients suffering subcutaneous emphysema.
All patients will be investigated 24h after performing the SAP block (or control) by a blinded assessor.
|
24 hours after performing the serratus anterior plane block at postoperative day 7
|
Number of patients with new onset perioperative atrial fibrillation (POAF)
Time Frame: Until postoperative day 7
|
Number of patients suffering witnessed (ECG recorded) POAF and patients with history of (paroxysmal) atrial fibrillation will not be taken into account for this secondary outcome parameter.
|
Until postoperative day 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JessaH_SAPblock
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia
-
Mansoura UniversityNot yet recruiting
-
Southeast University, ChinaRecruiting
-
Medical University of South CarolinaRecruiting
-
Southeast University, ChinaRecruiting
-
Huazhong University of Science and TechnologyRecruiting
-
Mansoura UniversityCompleted
-
University of FloridaMdoloris Medical SystemsCompletedAnalgesiaUnited States
-
Mansoura UniversityCompleted
-
Cessatech A/SCompleted
-
Kalyra Pharmaceuticals, Inc.United States Department of Defense; PRA Health SciencesTerminated
Clinical Trials on Serratus anterior plane block
-
Mansoura UniversityCompletedShoulder SurgeryEgypt
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingThoracic SurgeryUnited States
-
Kyungpook National University HospitalUnknownPain Management | ThoracotomyKorea, Republic of
-
Bezmialem Vakif UniversityRecruiting
-
Liu DiRecruitingLiver Neoplasms | Serratus Anterior Plane Block | Postoperative AnalgesiaChina
-
Cairo UniversitySamuel Bekhet Moawad; Ahmed Shaker Ragab; Michael Wahib WadidCompletedU/S Guided SAB VS U/S Guided SAB Combined With Modified Pectoral Nerve BlockEgypt
-
Ain Shams UniversityNot yet recruiting
-
National Cancer Institute, EgyptCompletedBreast Cancer | Postoperative PainEgypt
-
National Cancer Institute, EgyptRecruitingBreast Cancer | Acute Pain | Post-mastectomy Pain SyndromeEgypt
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingChronic Pain | Postoperative Pain | Acute Pain | Erector Spinae Plane Block | Serratus Anterior Plane Block | Video-Assisted Thoracoscopic SurgeryTurkey